(Q89347786)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Dendritic cell-based immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

3

Nina Bhardwaj

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Rachel L Sabado

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

27 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

74-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

Decisions about dendritic cells: past, present, and future

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Origin and development of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Circulating precursors of human CD1c+ and CD141+ dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Defining human dendritic cell progenitors by multiparametric flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human dendritic cell subsets

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Transcriptional Control of Dendritic Cell Development.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Plasmacytoid dendritic cells: linking innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Inflammatory dendritic cells in mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human dermal CD14⁺ cells are a transient population of monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

How vitamin A metabolizing dendritic cells are generated in the gut mucosa

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells in a mature age.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells control B cell growth and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Toll-like receptor signalling

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Sensing pathogens and danger signals by the inflammasome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Danger signals: a time and space continuum.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Pathways of antigen processing

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cross-Presentation in Mouse and Human Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigen presentation and T cell stimulation by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cross-presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Signalling through C-type lectin receptors: shaping immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The Dendritic Cell Synapse: A Life Dedicated to T Cell Activation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

IDO expression by dendritic cells: tolerance and tryptophan catabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

IDO and tolerance to tumors

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Spontaneous regression of metastases from melanoma: review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human tumor antigens for cancer vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cancer immunoediting from immune surveillance to immune escape

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The three Es of cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and applicability

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1(+) DCs in mouse and human and distinguishes them from Langerhans cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The allogeneic response and tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Clonal analysis of human dendritic cell progenitor using a stromal cell culture

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CD54 is a surrogate marker of antigen presenting cell activation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells under the spell of prostaglandins

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

The role of CD40 and CD154/CD40L in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Toll-like receptors control activation of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigen loading of dendritic cells with whole tumor cell preparations

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Viral vectors for dendritic cell-based immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Lentiviral vectors in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Genetic engineering of T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cancer immunotherapy with mRNA-transfected dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Visualization of immediate immune responses to pioneer metastatic cells in the lung.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Improving vaccines by targeting antigens to dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting antigens to dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Cytokine gene-mediated immunotherapy: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Altered macrophage differentiation and immune dysfunction in tumor development

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

C-type lectins on dendritic cells: key modulators for the induction of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells dysfunction in tumour environment

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Role of altered expression of HLA class I molecules in cancer progression.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Suppressive influences in the immune response to cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

First oncolytic virus approved for melanoma immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Oncolytic viruses: focusing on the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Pluripotent stem cells as source of dendritic cells for immune therapy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Dendritic cells derived from pluripotent stem cells: Potential of large scale production

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

CRISPR/Cas9 and cancer targets: future possibilities and present challenges

1 reference

https://api.crossref.org/works/10.1038%2FCR.2016.157

7 January 2021

Apoptotic cells at the crossroads of tolerance and immunity

1 reference

12 December 2020

Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors

1 reference

12 December 2020

Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines

1 reference

12 December 2020

Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines

1 reference

12 December 2020

Differentiation of peripheral blood monocytes into dendritic cells

1 reference

12 December 2020

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

1 reference

12 December 2020

Specialized role of migratory dendritic cells in peripheral tolerance induction

1 reference

12 December 2020

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state

1 reference

12 December 2020

Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer

1 reference

12 December 2020

Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy

1 reference

12 December 2020

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/CR.2016.157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28025976%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference